SS-31 (Elamipretide) for Recovery and Mitochondrial Health

What is SS-31?

SS-31 (Szeto-Schiller 31), also known as elamipretide or Bendavia, is a cell-permeable peptide that targets mitochondria. Athletes discuss it as a recovery aid. This page weighs that claim against the evidence; our SS-31 overview covers the compound and its approval.

Background

Synthetic tetrapeptide (4 amino acids)
Specifically designed to target mitochondria
Developed by Hazel Szeto and Peter Schiller
As of October 2026, FDA-approved as Forzinity only for Barth syndrome (accelerated approval, September 19, 2025)

Chemical Properties

Sequence: D-Arg-Dmt-Lys-Phe-NH2
Carries positive charge
Concentrates in mitochondrial membrane

Mechanism of Action

Mitochondrial Targeting

In cell and animal studies, SS-31 localizes to the inner mitochondrial membrane, where Szeto's 2014 review describes it doing the following:

Binds to cardiolipin (essential mitochondrial lipid)
Stabilizes electron transport chain
Reduces electron leakage

For detail, see how SS-31 binds cardiolipin and the research on SS-31 and ATP production.

Cellular Effects

SS-31 -> Mitochondrial Inner Membrane
    
    +-> Cardiolipin stabilization
    +-> Improved electron transport
    +-> Reduced ROS production
    +-> Enhanced ATP synthesis
    +-> Protected mitochondrial function

Antioxidant Effects

Reduces reactive oxygen species (ROS) in cell and animal studies
Not a traditional antioxidant scavenger

Claimed Benefits for Athletes

Forum posts and vendor copy commonly list these benefits. As of October 2026, none has been tested in healthy athletes.

Reduced exercise-induced oxidative stress
Faster cellular recovery
Reduced muscle fatigue
Better exercise tolerance
Protection against overtraining effects

Research Evidence

Preclinical Studies

Study	Finding	Caveat
Aged mice, single 3 mg/kg dose (2013)	ATP production back to young levels within an hour; 8 days of dosing raised treadmill endurance	No effect on young muscle
Aged mice, 3 mg/kg/day for 8 weeks (2019)	Higher ATP capacity; longer treadmill endurance	Old, untrained mice

Both studies used muscle already impaired by age. The 2013 study found nothing measurable in young mice, the closer match to athletes.

Clinical Development

Healthy older adults: in a 2021 randomized trial of 39 people aged 60-85 with poorly functioning muscle mitochondria, one IV infusion raised ATP capacity right after dosing. The effect was gone by day 7, and fatigue resistance didn't change.
Primary mitochondrial myopathy: MMPOWER-3 (218 adults, 40 mg/day for 24 weeks) missed both primary endpoints, walking distance and fatigue.
Heart attack: the EMBRACE STEMI Phase 2a trial didn't reduce infarct size.
Barth syndrome: FDA based the approval on knee strength in 12 patients and requires a confirmatory trial.

As of October 2026, no study has tested SS-31 for exercise recovery in healthy athletes.

Dosing Protocols

These figures are reported, not recommended.

Approved label: 40 mg by subcutaneous injection once daily for Barth syndrome patients weighing at least 30 kg. Forzinity is a prescription medicine, and research-use vials aren't equivalent.
Trials: MMPOWER-3 also used 40 mg/day.
Users: forum users describe about 0.5-4 mg/day for around four weeks; one posted protocol reached 10 mg/day. No study has tested these amounts.

Administration

Subcutaneous injection primary route
IV used in clinical settings
Once daily dosing typical

Timing for Athletes

Users describe these choices; no study has tested them.

Timing	Purpose	Rationale
Post-workout	Recovery support	Counter exercise-induced ROS
Pre-workout	Protection	Prime mitochondria before stress
Daily	General support	Maintain mitochondrial health

Applications for Recovery

Post-Exercise Recovery

The reasoning is that hard training raises ROS and SS-31 lowers them. In aged mice it did. Whether that carries over to young, trained muscle is unknown.

Overtraining Prevention

No study has looked at overtraining or at training adaptation.

Injury Recovery

Some guides pair SS-31 with BPC-157 or TB-500 for injuries, but nobody has tested the combination.

Comparison to Other Recovery Approaches

Approach	Target	Mechanism	Uniqueness
SS-31	Mitochondria	Cardiolipin binding	Direct mito protection
BPC-157	Tissues	Growth factor modulation	Tissue repair
TB-500	Cells	Actin regulation	Cell migration
Antioxidants	ROS	Scavenging	General, less targeted

None of these has been compared head-to-head for exercise recovery in people.

Stacking Protocols

Nobody has studied these community stacks as combinations; amounts are what users or vendors report for each compound alone. WADA's 2026 Prohibited List names BPC-157 and MOTS-c, while SS-31's status since its approval is unverified (see how WADA treats MOTS-c and SS-31).

Peptide	Reported amount	Source of figure	Purpose
SS-31	0.5-4 mg/day	Forum users	Mitochondrial protection
BPC-157	250-500 mcg/day	Users	Tissue repair
TB-500	2-2.5 mg 2x weekly	Vendor guidance	Cellular repair
MOTS-c	5 mg 2-3x weekly	Users	Metabolic

Safety Considerations

Clinical Trial Safety

In the Barth trial, all 12 patients had injection-site redness on the drug, compared with 3 of 12 on placebo (Forzinity label)
The label warns of allergic reactions, some serious
MMPOWER-3 reported mostly mild-to-moderate adverse events

Potential Concerns

Limited long-term human data, none in healthy people
Headache and fatigue in user reports
Quality control essential

Practical Considerations

Source Quality

Research chemical market
FDA's August 2026 warning letter to one seller called research-use "SS-31 (Elamipretide)" an unapproved new drug
Cost can be significant

Limitations

Research Gaps

Dose-response for athletes
Long-term athletic use safety
Synergy with other peptides

What to Watch Next

As of October 2026, the confirmatory Barth syndrome trial is the main pending test of whether SS-31's strength effect means real benefit for patients. The nearest registered study is a small Phase 2 safety trial in sedentary adults aged 65-80 (NCT07275424), listed as recruiting. We found no registered trial in trained people.